- Home
- RMAX vs TLSA Comparison
RMAX vs TLSA Comparison
Compare RMAX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- TLSA
- Stock Information
- Founded
- RMAX 1973
- TLSA 2013
- Country
- RMAX United States
- TLSA United Kingdom
- Employees
- RMAX N/A
- TLSA N/A
- Industry
- RMAX Real Estate
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- RMAX Finance
- TLSA Health Care
- Exchange
- RMAX Nasdaq
- TLSA Nasdaq
- Market Cap
- RMAX 187.5M
- TLSA 187.0M
- IPO Year
- RMAX 2013
- TLSA 2000
- Fundamental
- Price
- RMAX $8.42
- TLSA $2.15
- Analyst Decision
- RMAX Hold
- TLSA
- Analyst Count
- RMAX 1
- TLSA 0
- Target Price
- RMAX $9.00
- TLSA N/A
- AVG Volume (30 Days)
- RMAX 200.3K
- TLSA 445.4K
- Earning Date
- RMAX 10-30-2025
- TLSA 05-06-2025
- Dividend Yield
- RMAX N/A
- TLSA N/A
- EPS Growth
- RMAX N/A
- TLSA N/A
- EPS
- RMAX 0.48
- TLSA N/A
- Revenue
- RMAX $298,162,000.00
- TLSA N/A
- Revenue This Year
- RMAX N/A
- TLSA N/A
- Revenue Next Year
- RMAX N/A
- TLSA N/A
- P/E Ratio
- RMAX $17.53
- TLSA N/A
- Revenue Growth
- RMAX N/A
- TLSA N/A
- 52 Week Low
- RMAX $6.90
- TLSA $0.63
- 52 Week High
- RMAX $14.31
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- RMAX 33.96
- TLSA 61.78
- Support Level
- RMAX $9.10
- TLSA $1.90
- Resistance Level
- RMAX $9.44
- TLSA $2.09
- Average True Range (ATR)
- RMAX 0.31
- TLSA 0.18
- MACD
- RMAX -0.18
- TLSA 0.02
- Stochastic Oscillator
- RMAX 1.57
- TLSA 75.96
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.